Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst session for the stock in nearly four years.

Fears of heightened oversight in the industry could weigh on not just Eli Lilly, but healthcare stocks as a whole. Plus, there is also the concern that the stock's high valuation may finally be ...

29,097 people played the daily Crossword recently. Can you solve it faster than others?29,097 people played the daily Crossword recently. Can you solve it faster than others?

Eli Lilly (LLY ... doses of tirzepatide was available throughout Q4," said Lilly CEO David Ricks in a statement. The move in the stock surprised some experts and analysts since the market had ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 billion ...

In Eli Lilly's most recent quarter, which ended on Sept. 30, 2024, it grew its sales by 20% to $11.4 billion. It also had multiple products that generated over $1 billion in revenue, including its ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...